amrinone has been researched along with Lung Diseases, Obstructive in 4 studies
Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.
amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.
Lung Diseases, Obstructive: Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent.
| Excerpt | Relevance | Reference |
|---|---|---|
| " No adverse effects were recorded in any of the patients." | 5.28 | Evaluation of the safety and efficacy of amrinone in chronic obstructive lung disease with cor pulmonale. ( Arens, M; De Waele, R; Demedts, M; Meirhaeghe, J; Van den Brande, P; Van Mieghem, W, 1990) |
| "Amrinone is a positive inotropic agent which has been widely used for treatment of left heart failure." | 3.67 | [Right ventricular hemodynamics and lung function following amrinone injection]. ( Baur, X; Fruhmann, G; Hauser, F; Klepzig, M; Mernitz, G; Strauer, BE, 1984) |
| "To illustrate the multiple causes of hypoxemia to be considered following cardiopulmonary bypass and how therapy given to improve oxygen delivery may have contributed to a decrease in arterial oxygen saturation to life-threatening levels." | 1.30 | Profound hypoxemia during treatment of low cardiac output after cardiopulmonary bypass. ( Dennehy, KC; Dupuis, JY; Nathan, HJ; Wynands, JE, 1999) |
| " No adverse effects were recorded in any of the patients." | 1.28 | Evaluation of the safety and efficacy of amrinone in chronic obstructive lung disease with cor pulmonale. ( Arens, M; De Waele, R; Demedts, M; Meirhaeghe, J; Van den Brande, P; Van Mieghem, W, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Klepzig, M | 1 |
| Baur, X | 1 |
| Hauser, F | 1 |
| Mernitz, G | 1 |
| Fruhmann, G | 1 |
| Strauer, BE | 1 |
| Dennehy, KC | 1 |
| Dupuis, JY | 1 |
| Nathan, HJ | 1 |
| Wynands, JE | 1 |
| Van Mieghem, W | 1 |
| Van den Brande, P | 1 |
| De Waele, R | 1 |
| Meirhaeghe, J | 1 |
| Arens, M | 1 |
| Demedts, M | 1 |
| Faitg, R | 1 |
| Coulaud, JM | 1 |
| Rezgui, N | 1 |
| Brulot, N | 1 |
| Clavier, H | 1 |
| Besse, B | 1 |
| Labrousse, J | 1 |
| Lissac, J | 1 |
4 other studies available for amrinone and Lung Diseases, Obstructive
| Article | Year |
|---|---|
[Right ventricular hemodynamics and lung function following amrinone injection].
Topics: Airway Resistance; Aminopyridines; Amrinone; Cardiotonic Agents; Heart Failure; Heart Ventricles; He | 1984 |
Profound hypoxemia during treatment of low cardiac output after cardiopulmonary bypass.
Topics: Amrinone; Cardiac Output; Cardiac Output, Low; Cardiopulmonary Bypass; Cardiotonic Agents; Dobutamin | 1999 |
Evaluation of the safety and efficacy of amrinone in chronic obstructive lung disease with cor pulmonale.
Topics: Aged; Amrinone; Cardiac Output; Dose-Response Relationship, Drug; Female; Humans; Lung Diseases, Obs | 1990 |
[Hemodynamic effects of amrinone and comparison with dobutamine in patients with chronic respiratory insufficiency with pulmonary hypertension].
Topics: Aged; Amrinone; Dobutamine; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Ob | 1989 |